Compare SUIG & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SUIG | ACOG |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | Canada |
| Employees | 3 | 57 |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.4M | 110.4M |
| IPO Year | N/A | N/A |
| Metric | SUIG | ACOG |
|---|---|---|
| Price | $1.49 | $6.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.75 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 259.4K | 68.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.95 | $142.06 |
| Revenue Next Year | N/A | $141.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $4.20 |
| 52 Week High | $7.25 | $10.88 |
| Indicator | SUIG | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 60.49 |
| Support Level | $1.09 | $6.46 |
| Resistance Level | $1.53 | $7.69 |
| Average True Range (ATR) | 0.11 | 0.65 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 98.67 | 66.42 |
Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.